ESPR

Bempedoic Acid/ Ezetimibe (Nexlizet)

Hypercholesterolemia

Quarterly Sales (Approved)

Exp Date

November 02, 2020

Amp Volatility Score

32%

Catalyst Info & Data Links

TITLE: Bempedoic Acid/ Ezetimibe (Nexlizet) (FDA-approved Drug) - Quarterly Sales


WHAT IS THE CATALYST EVENT?

  • Quarterly Sales


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?


PRIOR DATA


PRESS RELEASES

MARKET

  • ~One in 250 adults (an estimated 834,000 people) have the Familial hypercholesterolemia genetic mutation (learn more). 

MECHANISM OF ACTION / RATIONALE

  • NEXLIZET contains bempedoic acid and ezetimibe. NEXLIZET reduces elevated LDL-C through inhibition of cholesterol synthesis in the liver and absorption in the intestine.

  • Bempedoic acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor that lowers low-density lipoprotein cholesterol (LDL-C) by inhibition of cholesterol synthesis in the liver. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway. Bempedoic acid and its active metabolite, ESP15228, require coenzyme A (CoA) activation by very long-chain acyl-CoA synthetase 1 (ACSVL1) to ETC-1002-CoA and ESP15228-CoA, respectively. ACSVL1 is expressed primarily in the liver. Inhibition of ACL by ETC-1002-CoA results in decreased cholesterol synthesis in the liver and lowers LDL-C in blood via upregulation of low-density lipoprotein receptors.

  • Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine. The molecular target of ezetimibe has been shown to be the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is involved in the intestinal uptake of cholesterol and phytosterols. Ezetimibe localizes at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the blood.

  • Source - FDA Label (section 12.1)

Updated by MV

#ESPR #Hypercholesterolemia #BempedoicAcid #Ezetimibe #Nexlizet #cardiovasculardisease #heartdisease

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

ESPR - Esperion to Report Thir...

#ESPR "announced it will report third quarter 2020 financial results after the close of the U.S. financial markets on Monday, November 2, 2020.
Following the release, company management will host a w...

ESPR - Q2 2020 Net Sales...

#ESPR reported Q2 2020 Financial Results. See our AmpCard for details. #ESPR, #Bempedoic_Acid, #Ezetimibe, #Nexlizet, #Nexletol
...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon